Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05789589 | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases(ADORATION) | suspended | Phase 1 / Phase 2 | 46 | Baptist Health South FloridaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer | suspended | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Jun 15, 2026 |
| clinicaltrials |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | suspended | Phase 1 | 10 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07340853 | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma | suspended | Phase 1 | 30 | Thomas Martin, MDOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06447987 | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | suspended | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05419479 | Switch Maintenance in Pancreatic | suspended | Phase 1 / Phase 2 | 46 | James Cleary, MD, PhDOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01386710 | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | suspended | Phase 1 / Phase 2 | 54 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02130492 | A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG) | suspended | Phase 1 / Phase 2 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07173374 | Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study(SCART-P) | suspended | Phase 1 | 24 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab(PANDA-VAC) | suspended | Phase 1 | 6 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05866679 | Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging | suspended | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | suspended | Phase 1 / Phase 2 | 15 | Cancer Research UKOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 366 | Curis, Inc.INDUSTRY | 8 | Mar 19, 2026 | clinicaltrials |
| NCT04890093 | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors | suspended | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06626633 | 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML | suspended | Phase 1 | 6 | University of Maryland, BaltimoreOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06219174 | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) | suspended | Phase 1 / Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03467386 | Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia | suspended | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | suspended | Phase 1 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | suspended | Phase 1 / Phase 2 | 30 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06649682 | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC(NYCRRLT) | suspended | Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04840472 | Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer | suspended | Phase 1 | 28 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06709131 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia(CT0991) | suspended | Phase 1 | 24 | He HuangOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia | suspended | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | suspended | Phase 1 | 98 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | suspended | Phase 1 | 6 | AmgenINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03417921 | A Study of ABTL0812 in Pancreatic Cancer(Pancreatic) | suspended | Phase 1 / Phase 2 | 60 | Ability Pharmaceuticals SLINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05958199 | A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 | suspended | Phase 1 | 131 | NextPoint Therapeutics, Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | suspended | Phase 1 / Phase 2 | 148 | Primocure PharmaINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03187210 | Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas(BAL) | suspended | Phase 1 / Phase 2 | 20 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06643494 | Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical | suspended | Phase 1 / Phase 2 | 100 | Optimal Health ResearchOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05191667 | AN0025 and Chemoradiotherapy Combination in Esophageal Cancer | suspended | Phase 1 | 32 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05076591 | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors | suspended | Phase 1 | 135 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03181035 | Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer(FAITH) | suspended | Phase 1 / Phase 2 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | suspended | Phase 1 | 24 | Veana TherapeuticsINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | suspended | Phase 1 | 30 | DNAtrix, Inc.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03932253 | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) | suspended | Phase 1 | 79 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05101616 | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer | suspended | Phase 1 / Phase 2 | 100 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02579005 | Radio-Immuno-Modulation in Lung Cancer(RIM) | suspended | Phase 1 | 24 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 210 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 9 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer(REPAIR) | suspended | Phase 1 | 48 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2026source: clinicaltrials